Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Joëlle Vermeulen, Katleen De Preter, Arlene Naranjo, Liesbeth Vercruysse, Nadine Van Roy, Jan Hellemans, Katrien Swerts, Sophie Bravo, Paola Scaruffi, Gian Paolo Tonini, Bruno De Bernardi, Rosa Noguera, Marta Piqueras, Adela Cañete, Victoria Castel, Isabelle Janoueix-Lerosey, Olivier Delattre, Gudrun Schleiermacher, Jean Michon, Valérie CombaretMatthias Fischer, André Oberthuer, Peter F. Ambros, Klaus Beiske, Jean Bénard, Bárbara Marques, Hervé Rubie, Janice Kohler, Ulrike Pötschger, Ruth Ladenstein, Michael D. Hogarty, Patrick McGrady, Wendy B. London, Geneviève Laureys, Frank Speleman, Jo Vandesompele

Research output: Contribution to journalArticle

Abstract

Background: More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods: 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings: The signature has a performance, sensitivity, and specificity of 85·4% (95% CI 77·7-93·2), 84·4% (66·5-94·1), and 86·5% (81·1-90·6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19·32 [95% CI 6·50-57·43] and 3·96 [1·97-7·97] for overall survival and progression-free survival, respectively, both p

Original languageEnglish
Pages (from-to)663-671
Number of pages9
JournalThe Lancet Oncology
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Neuroblastoma
Disease-Free Survival
Odds Ratio
Data Mining
Survival
Transcriptome
Real-Time Polymerase Chain Reaction
Multivariate Analysis
RNA
Recurrence
Sensitivity and Specificity
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Vermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., ... Vandesompele, J. (2009). Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. The Lancet Oncology, 10(7), 663-671. https://doi.org/10.1016/S1470-2045(09)70154-8

Predicting outcomes for children with neuroblastoma using a multigene-expression signature : a retrospective SIOPEN/COG/GPOH study. / Vermeulen, Joëlle; De Preter, Katleen; Naranjo, Arlene; Vercruysse, Liesbeth; Van Roy, Nadine; Hellemans, Jan; Swerts, Katrien; Bravo, Sophie; Scaruffi, Paola; Tonini, Gian Paolo; De Bernardi, Bruno; Noguera, Rosa; Piqueras, Marta; Cañete, Adela; Castel, Victoria; Janoueix-Lerosey, Isabelle; Delattre, Olivier; Schleiermacher, Gudrun; Michon, Jean; Combaret, Valérie; Fischer, Matthias; Oberthuer, André; Ambros, Peter F.; Beiske, Klaus; Bénard, Jean; Marques, Bárbara; Rubie, Hervé; Kohler, Janice; Pötschger, Ulrike; Ladenstein, Ruth; Hogarty, Michael D.; McGrady, Patrick; London, Wendy B.; Laureys, Geneviève; Speleman, Frank; Vandesompele, Jo.

In: The Lancet Oncology, Vol. 10, No. 7, 07.2009, p. 663-671.

Research output: Contribution to journalArticle

Vermeulen, J, De Preter, K, Naranjo, A, Vercruysse, L, Van Roy, N, Hellemans, J, Swerts, K, Bravo, S, Scaruffi, P, Tonini, GP, De Bernardi, B, Noguera, R, Piqueras, M, Cañete, A, Castel, V, Janoueix-Lerosey, I, Delattre, O, Schleiermacher, G, Michon, J, Combaret, V, Fischer, M, Oberthuer, A, Ambros, PF, Beiske, K, Bénard, J, Marques, B, Rubie, H, Kohler, J, Pötschger, U, Ladenstein, R, Hogarty, MD, McGrady, P, London, WB, Laureys, G, Speleman, F & Vandesompele, J 2009, 'Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study', The Lancet Oncology, vol. 10, no. 7, pp. 663-671. https://doi.org/10.1016/S1470-2045(09)70154-8
Vermeulen, Joëlle ; De Preter, Katleen ; Naranjo, Arlene ; Vercruysse, Liesbeth ; Van Roy, Nadine ; Hellemans, Jan ; Swerts, Katrien ; Bravo, Sophie ; Scaruffi, Paola ; Tonini, Gian Paolo ; De Bernardi, Bruno ; Noguera, Rosa ; Piqueras, Marta ; Cañete, Adela ; Castel, Victoria ; Janoueix-Lerosey, Isabelle ; Delattre, Olivier ; Schleiermacher, Gudrun ; Michon, Jean ; Combaret, Valérie ; Fischer, Matthias ; Oberthuer, André ; Ambros, Peter F. ; Beiske, Klaus ; Bénard, Jean ; Marques, Bárbara ; Rubie, Hervé ; Kohler, Janice ; Pötschger, Ulrike ; Ladenstein, Ruth ; Hogarty, Michael D. ; McGrady, Patrick ; London, Wendy B. ; Laureys, Geneviève ; Speleman, Frank ; Vandesompele, Jo. / Predicting outcomes for children with neuroblastoma using a multigene-expression signature : a retrospective SIOPEN/COG/GPOH study. In: The Lancet Oncology. 2009 ; Vol. 10, No. 7. pp. 663-671.
@article{20ee948845644c8fb17f15167dc4bcac,
title = "Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study",
abstract = "Background: More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods: 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings: The signature has a performance, sensitivity, and specificity of 85·4{\%} (95{\%} CI 77·7-93·2), 84·4{\%} (66·5-94·1), and 86·5{\%} (81·1-90·6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19·32 [95{\%} CI 6·50-57·43] and 3·96 [1·97-7·97] for overall survival and progression-free survival, respectively, both p",
author = "Jo{\"e}lle Vermeulen and {De Preter}, Katleen and Arlene Naranjo and Liesbeth Vercruysse and {Van Roy}, Nadine and Jan Hellemans and Katrien Swerts and Sophie Bravo and Paola Scaruffi and Tonini, {Gian Paolo} and {De Bernardi}, Bruno and Rosa Noguera and Marta Piqueras and Adela Ca{\~n}ete and Victoria Castel and Isabelle Janoueix-Lerosey and Olivier Delattre and Gudrun Schleiermacher and Jean Michon and Val{\'e}rie Combaret and Matthias Fischer and Andr{\'e} Oberthuer and Ambros, {Peter F.} and Klaus Beiske and Jean B{\'e}nard and B{\'a}rbara Marques and Herv{\'e} Rubie and Janice Kohler and Ulrike P{\"o}tschger and Ruth Ladenstein and Hogarty, {Michael D.} and Patrick McGrady and London, {Wendy B.} and Genevi{\`e}ve Laureys and Frank Speleman and Jo Vandesompele",
year = "2009",
month = "7",
doi = "10.1016/S1470-2045(09)70154-8",
language = "English",
volume = "10",
pages = "663--671",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Predicting outcomes for children with neuroblastoma using a multigene-expression signature

T2 - a retrospective SIOPEN/COG/GPOH study

AU - Vermeulen, Joëlle

AU - De Preter, Katleen

AU - Naranjo, Arlene

AU - Vercruysse, Liesbeth

AU - Van Roy, Nadine

AU - Hellemans, Jan

AU - Swerts, Katrien

AU - Bravo, Sophie

AU - Scaruffi, Paola

AU - Tonini, Gian Paolo

AU - De Bernardi, Bruno

AU - Noguera, Rosa

AU - Piqueras, Marta

AU - Cañete, Adela

AU - Castel, Victoria

AU - Janoueix-Lerosey, Isabelle

AU - Delattre, Olivier

AU - Schleiermacher, Gudrun

AU - Michon, Jean

AU - Combaret, Valérie

AU - Fischer, Matthias

AU - Oberthuer, André

AU - Ambros, Peter F.

AU - Beiske, Klaus

AU - Bénard, Jean

AU - Marques, Bárbara

AU - Rubie, Hervé

AU - Kohler, Janice

AU - Pötschger, Ulrike

AU - Ladenstein, Ruth

AU - Hogarty, Michael D.

AU - McGrady, Patrick

AU - London, Wendy B.

AU - Laureys, Geneviève

AU - Speleman, Frank

AU - Vandesompele, Jo

PY - 2009/7

Y1 - 2009/7

N2 - Background: More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods: 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings: The signature has a performance, sensitivity, and specificity of 85·4% (95% CI 77·7-93·2), 84·4% (66·5-94·1), and 86·5% (81·1-90·6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19·32 [95% CI 6·50-57·43] and 3·96 [1·97-7·97] for overall survival and progression-free survival, respectively, both p

AB - Background: More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods: 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings: The signature has a performance, sensitivity, and specificity of 85·4% (95% CI 77·7-93·2), 84·4% (66·5-94·1), and 86·5% (81·1-90·6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19·32 [95% CI 6·50-57·43] and 3·96 [1·97-7·97] for overall survival and progression-free survival, respectively, both p

UR - http://www.scopus.com/inward/record.url?scp=67649372693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649372693&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(09)70154-8

DO - 10.1016/S1470-2045(09)70154-8

M3 - Article

C2 - 19515614

AN - SCOPUS:67649372693

VL - 10

SP - 663

EP - 671

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -